AstraZeneca, together with partner organisations, launches 2017 Global Diabetes Policy Forum for action in diabetes

AstraZeneca, in partnership with International Diabetes Federation, the World Heart Federation and Primary Care Diabetes Europe, bring together in Rome more than 100 experts from 25 countries to build momentum for tangible policy changes addressing outcomes for all people with type-2 diabetes

17 October 2017

Today, AstraZeneca announces its participation in the 2017 Global Diabetes Policy Forum in Rome, Italy, taking place 17-18 October, as part of the multi-year Action in Diabetes initiative. The event, now in its third year, brings together more than 100 leading global experts in type-2 diabetes care to discuss best practices in policy-making, with the goal of driving forward meaningful progress for patients with type-2 diabetes around the world. Inspired and funded by AstraZeneca, the initiative operates in partnership with the International Diabetes Federation, the World Heart Federation and Primary Care Diabetes Europe, as well as several local Italian endocrinology organisations.

“AstraZeneca is proud to be working together with such respected partners. Our common goal is to improve policy, access and treatment paradigms for people with diabetes, while addressing the comorbidities of this highly prevalent disease,” said Danilo Verge, Vice President CVMD Global Medical Affairs, AstraZeneca. “Diabetes affects millions across the globe, and we are taking steps now to support nationally-driven initiatives for prevention, diagnosis and disease management."

 

 

“The International Diabetes Federation is delighted to champion this important initiative that aims to achieve concrete benefits for people with diabetes in all countries and settings," said Dr. Shaukat Sadikot, President, International Diabetes Federation. "The widespread proportions of diabetes shows no signs of relenting and so it is critical that a broad range of stakeholders come together to encourage and support much needed policy reform.”

Based on current trends, 642 million people are expected to have type-2 diabetes by the year 20401. Diabetes continues to be a worldwide public health concern and is associated with significant comorbidities that contribute to an increased risk of costly hospitalisations2. Given the interconnectivity of metabolic, cardiovascular and renal diseases, research has shown that cardiovascular-related events are the underlying cause of death for more than half of people with type-2 diabetes3. The Action in Diabetes partners are working towards meaningful reform through tangible action on a national level to tackle poor outcomes for all people with, and at risk of, type-2 diabetes and its complications.   

“The increase in diabetes prevalence is putting millions of people at increased risk of cardiovascular diseases,” said Dr. Pablo Perel, Senior Science Advisor, World Heart Federation. “The Action in Diabetes movement and its policy goals are very welcome as it will ensure the commitment of national experts to engage the wider community of physicians, policy-makers and other diabetes treatment-related professionals to advocate for concrete actions to improve the lives of those suffering from diabetes and its severe complications.”

Follow the discussion on Twitter using the hashtag #ActionDiabetes.

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. 


CONTACTS

Media Relations

 

 

 

 

Rob Skelding

UK/Global

+44 203 749 5821

Blake McEvoy

Global

+1 302 304 0979

 

 

 

Investor Relations

 

 

Christer Gruvris

Diabetes; Autoimmunity, Neuroscience & Infection

+44 203 749 5711

US Toll-Free

 

+1 866 381 7277

 

References:

  1. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org
  2. Khalid, J. M., Raluy-Callado, M., Curtis, B. H., Boye, K. S., Maguire, A. and Reaney, M. (2014), Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics. Int J Clin Pract, 68: 40–48. doi:10.1111/ijcp.12265
  3. Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14-21. Available online:  https://www.ncbi.nlm.nih.gov/pubmed/11587045.

tags

  • Science